Cigna Group (NYSE: CI) has a higher price-to-earnings ratio of 27.54x compared to its average ratio. CI has 36-month beta value of 0.51. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 6 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for CI is 274.31M, and currently, short sellers hold a 1.26% ratio of that float. The average trading volume of CI on September 05, 2024 was 1.34M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CI) stock’s latest price update
Cigna Group (NYSE: CI)’s stock price has plunge by -4.50relation to previous closing price of 366.64. Nevertheless, the company has seen a -2.18% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-05 that Estimated to save individual Accredo patients around $4,000 per year Biosimilar price will be more than 80% lower than Stelara list price Accredo patients benefit from the specialty pharmacy’s best-in-class clinical support BLOOMFIELD, Conn., Sept. 5, 2024 /PRNewswire/ — Evernorth Health Services announced that it plans to have a Stelara biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy, Accredo, beginning in early 2025.
CI’s Market Performance
Cigna Group (CI) has experienced a -2.18% fall in stock performance for the past week, with a 6.33% rise in the past month, and a 4.77% rise in the past quarter. The volatility ratio for the week is 1.56%, and the volatility levels for the past 30 days are at 1.70% for CI. The simple moving average for the last 20 days is 1.14% for CI stock, with a simple moving average of 6.14% for the last 200 days.
Analysts’ Opinion of CI
Many brokerage firms have already submitted their reports for CI stocks, with Piper Sandler repeating the rating for CI by listing it as a “Overweight.” The predicted price for CI in the upcoming period, according to Piper Sandler is $400 based on the research report published on June 26, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CI reach a price target of $388. The rating they have provided for CI stocks is “Outperform” according to the report published on May 30th, 2024.
Barclays gave a rating of “Overweight” to CI, setting the target price at $393 in the report published on March 06th of the current year.
CI Trading at 3.12% from the 50-Day Moving Average
After a stumble in the market that brought CI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.53% of loss for the given period.
Volatility was left at 1.70%, however, over the last 30 days, the volatility rate increased by 1.56%, as shares surge +6.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.20% upper at present.
During the last 5 trading sessions, CI fell by -2.32%, which changed the moving average for the period of 200-days by +23.88% in comparison to the 20-day moving average, which settled at $347.20. In addition, Cigna Group saw 16.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CI starting from DeLaney William J III, who sale 2,691 shares at the price of $342.68 back on Aug 19 ’24. After this action, DeLaney William J III now owns 17,539 shares of Cigna Group, valued at $922,152 using the latest closing price.
DeLaney William J III, the Director of Cigna Group, proposed sale 2,691 shares at $342.68 during a trade that took place back on Aug 19 ’24, which means that DeLaney William J III is holding shares at $922,152 based on the most recent closing price.
Stock Fundamentals for CI
Current profitability levels for the company are sitting at:
- 0.04 for the present operating margin
- 0.83 for the gross margin
The net margin for Cigna Group stands at 0.01. The total capital return value is set at 0.08. Equity return is now at value 8.55, with 2.51 for asset returns.
Based on Cigna Group (CI), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.3. The debt to equity ratio resting at 0.77. The interest coverage ratio of the stock is 11.47.
Currently, EBITDA for the company is 5.16 billion with net debt to EBITDA at 7.3. When we switch over and look at the enterprise to sales, we see a ratio of 0.57. The receivables turnover for the company is 7.27for trailing twelve months and the total asset turnover is 1.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.83.
Conclusion
To put it simply, Cigna Group (CI) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
